EEC | Jotup

Thailand Elevator and Escalator Market Insights Report 2024-2029: Sustainable Construction Practices to Increase the Demand for Elevator Installation in Residential Buildings - ResearchAndMarkets.com

Retrieved on:

Monday, April 1, 2024

The "Thailand Elevator and Escalator Market - Size & Growth Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Thailand Elevator and Escalator Market - Size & Growth Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The key players in the Thailand elevator and escalator market are KONE, Otis, Hyundai Elevator, TK Elevator, Mitsubishi Electric, Hitachi, Schindler, and Fujitec.
The plan will contribute to the Thailand elevator and escalator market expansion during the forecast period.
It will be in Pattaya and is projected to support the Thailand elevator and escalator market expansion.

Thailand Construction Equipment Rental Market Assessment & Forecasts 2023-2024 and 2029: Increased Focus on Lithium Mining, Waste Management Triggers the Use of Excavators & Loaders - ResearchAndMarkets.com

Retrieved on:

Thursday, March 28, 2024

The "Thailand Construction Equipment Rental Market - Strategic Assessment & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Thailand Construction Equipment Rental Market - Strategic Assessment & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.
Rising investment in housing, port expansion, and public infrastructure projects is expected to drive the Thailand construction equipment rental market.
The project will feature both floating and ground-mounted solar installations and support the growth of the Thailand construction equipment rental market.
Which are the primary distributor companies in the Thailand construction equipment rental market?

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Retrieved on:

Sunday, March 17, 2024

LOS ANGELES, March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status. This new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.

Key Points:

The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status.
This new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.
"Overactivation of the mTOR pathway has been implicated in gynecological cancers," said Loretta Itri, MD, Chief Medical Officer at Aadi.
"nab-Sirolimus is a nanoparticle albumin-bound (nab) mTOR inhibitor under investigation in TSC1- and TSC2-mutated tumors as well as other mTOR-driven tumors.

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on:

Wednesday, March 13, 2024

Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points:

The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
"We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on:

Tuesday, March 12, 2024

Filtration, Vespula, Toxicity, Histamine, EAACI, Immunotherapy, Asthma, Report, Allergy, Skin, Pregnancy, PR, EEC, MITES, RNA, Criterion, History, CMR, Contraindication, HEP, Draft, Guideline, Patient, Ames test, Diagnosis, Dermatitis, Venom, Literature, Trial of the century, Reproduction, Silicon–germanium, SPT, Food allergy, Cosmetics, EECS, Absorption, Marketing, Safety, Data collection, Directive 2001/83/EC, GMP, ID50, Antibody, Documentation, European, Type IV hypersensitivity, Genotoxicity, Applicant (sketch), Aeroallergen, CHMP, PRIME, Immunoglobulin G, Type, Publication, Biology, Pollen, DNA, Environment, Immune system, Toolbox, NLN, AIT, Atopic dermatitis, Fatality, Chapter, Anaphylaxis, Process validation, ICH, Antigen, Rhinitis, Clinical trial, Erythema, Knowledge, Prescription, Human, Network, Medication, Scope, VIT, ICT, EMA, Collection, Macrophage, Outline, Metabolism, Registry, Inflammation, Immunoglobulin E, Nature, European Pharmacopoeia, Food, Risk, Prevalence, Mastocytosis, Observation, Cytokine, NPP, Patient safety, Disease, Finished, Medical device

16

Key Points:

16
Guideline on allergen products development for
immunotherapy and allergy diagnosis in moderate to lowsized study populations

17

Table of contents

18

Executive summary ..................................................................................... 3

19

1.
Specific effects ................................................................................................. 17
14
15

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 2/18

53

12.
Management for allergies may involve avoidance of the allergen, medications to relieve
66

symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.
71
Recommendations are made on the clinical development, potential study designs and safety

72

considerations for allergen products within the scope of the guideline.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 3/18

88

While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

89

there is no such treatment available for type IV allergies.
93
Several guidelines applicable for allergen products are available (see section 3) and provide advice on

94

quality and clinical development according to the current knowledge.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 4/18

127

However, this guideline does not cover the indication of atopic dermatitis or asthma as these

128

conditions will require separate clinical trials (see Section 6).
129
In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

130

DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

131

substantially to the allergen products as discussed above.
1
156

?

Guideline on the clinical development of products for specific immunotherapy for the treatment

157
158

of allergic diseases - CHMP/EWP/18504/2006
?

159
160
161

Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

?

Guideline on process validation for finished products - information and data to be provided in
regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 5/18

162

?

Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

163

4.
In any
199

case, a reduced validation should include all relevant manufacturing process steps that are considered
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 6/18

200

product specific.
290
Diagnostic allergen products (Type I allergy)

291

A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

292

intracutaneous or provocation testing.
298
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 9/18

305
306

7.1.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 11/18

377

8.
Clinical development of products for AIT: Study design,
efficacy and safety
378

In general, the clinical development should be performed according to current guidelines.
In such single trial, the suitability as a test allergen as well as the
376

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 12/18

415

dose finding for the therapeutic allergen could be investigated.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 13/18

454
455

8.2.1.
493
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 15/18

527

In general, sensitivity and specificity of the product should be determined.
540
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 16/18

561

10.2.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 17/18

595

4.
Allergol Immunopathol, 1989;
602

17(2):53-65

603

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 18/18

Orex Signs Option Agreement to Acquire 100% of the Valenciana Gold-Silver Project in Zacatecas State, Mexico

Retrieved on:

Tuesday, February 13, 2024

Pan American Silver, SSR Mining Inc., Silver, PB, Zinc, Mining, Nieves, Mexican Plateau, Documentation, EEC, Lead, Disclosure, National instrument, AG

de C.V. ("EEC"), a Mexican registered private company, to acquire 100% of the Valenciana Gold-Silver Project in Zacatecas State, Mexico (the "Valenciana Property").

Key Points:

de C.V. ("EEC"), a Mexican registered private company, to acquire 100% of the Valenciana Gold-Silver Project in Zacatecas State, Mexico (the "Valenciana Property").
It is located on the Mesa Central within the prolific "Silver Trend" of Mexico.
Orex's President & CEO, Ben Whiting, P.Geo., said; "This is a time of opportunities in the Mexican Mining Industry.
The Valenciana Mining District fits that description, and this is an excellent opportunity to restart exploration at Valenciana."

Data Center Networking Market Revenue to Record USD 38.33 Billion by 2030, Exhibiting a Robust CAGR of 7.53%, With North America Leading the Market as Widespread Application of 5G Technology Rises, Projects Kings Research

Retrieved on:

Monday, February 12, 2024

Health, Growth, NT, Public sector, EEC, Cloud computing, LAN, BFSI, Internet, Software

As part of the collaboration, NT will provide data center networking services for the campus.

Key Points:

As part of the collaboration, NT will provide data center networking services for the campus.
Based on end-user, the data center networking market is segmented into IT & telecom, BFSI, retail, healthcare, public sector & utilities, manufacturing, energy, and others.
The emergence of cloud services rooted in data centers further fuels the need for high-speed Internet and data center services.
North America is anticipated to retain its dominance in the global data center networking market.

Data Center Networking Market Revenue to Record USD 38.33 Billion by 2030, Exhibiting a Robust CAGR of 7.53%, With North America Leading the Market as Widespread Application of 5G Technology Rises, Projects Kings Research

Retrieved on:

Monday, February 12, 2024

Health, Growth, NT, Public sector, EEC, Cloud computing, LAN, BFSI, Internet, Software

As part of the collaboration, NT will provide data center networking services for the campus.

Key Points:

As part of the collaboration, NT will provide data center networking services for the campus.
Based on end-user, the data center networking market is segmented into IT & telecom, BFSI, retail, healthcare, public sector & utilities, manufacturing, energy, and others.
The emergence of cloud services rooted in data centers further fuels the need for high-speed Internet and data center services.
North America is anticipated to retain its dominance in the global data center networking market.

Thailand BOI Says 2023 Investment Applications up 43% to USD 24 Billion as Large FDI Projects Soar

Retrieved on:

Friday, February 9, 2024

Policy, Republic, EEC, BCG, Government House, Investment, FDI, Growth, EV, Electronics, Steel, Innovation, Steam, LTD, BOI, RDF, USD, Renewable energy

Moreover, the fact that the Prime Minister Srettha Thavisin, himself, led several investment promotion roadshows, has significantly raised investors' confidence and put Thailand on the radars of key investment communities."

Key Points:

Moreover, the fact that the Prime Minister Srettha Thavisin, himself, led several investment promotion roadshows, has significantly raised investors' confidence and put Thailand on the radars of key investment communities."
We also believe investments are likely to grow due to the continued flow of FDI, especially in our priority sectors."
The total number of applications for investment promotion filed last year by investors, both local and foreign, increased 16% to 2,307 projects, worth a combined 24 billion dollars investment, up 43% from a revised 16.9 billion dollars in 2022.
Singapore came in second with 194 projects worth a combined 3.5 billion dollars of investment, boosted by large projects applications from Singapore-based affiliates of international companies in sectors including solar cells and electronics.

Italy: ECOMONDO gets the ball rolling, IEG's Circular Economy Expo, an international hub for research and technological innovation

Retrieved on:

Monday, October 30, 2023

RIMINI, Italy, Oct. 30, 2023 /PRNewswire/ -- With over 300 qualified foreign buyers, 30 international delegations, more than 1,500 exhibiting brands (+10% compared to 2022) and the massive participation of the European Commission, the largest and most international edition of Ecomondo, the leading European circular economy expo organized by Italian Exhibition Group.

Key Points:

On a global level, every country is called upon to intensify their commitment to achieve the SDG objectives by 2030 and the demand for Made in Italy environmental technologies and solutions is increasingly strong.
Environmental opportunities and solutions will be presented in the calendar of over 170 scheduled events, many of which are international, under the direction of the Scientific Technical Committee.
The intense scouting activity attracted high-profile international buyers in the sectors of waste management, blue economy, bioeconomy, industry, services, construction, engineering, agroecology, etc.
Italian Exhibition Group Press Contacts, Head of media relation & corporate communication: Elisabetta Vitali; press office manager: Marco Forcellini; international press office coordinator: Silvia Giorgi; [email protected]